Announcements
- Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires
- Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
- Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024
- Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
- Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
- Inventiva annonce deux présentations scientifiques lors de l’EASL International Liver Congress™ 2024
- Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activités
- Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
- Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH
- Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
More ▼
Key statistics
On Friday, Inventiva SA (6IVA:FRA) closed at 3.18, 19.55% above the 52 week low of 2.66 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.94 |
---|---|
High | 3.18 |
Low | 2.92 |
Bid | 3.00 |
Offer | 3.56 |
Previous close | 3.22 |
Average volume | 0.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jun 07 2024 14:29 BST.
More ▼